Eysuvis, a new FDA-approved corticosteroid that is indicated for the short-term treatment, up to two weeks, of the signs and symptoms of dry eye disease. Patients often have periods of exacerbation called dry eye flares, where their dry eye symptoms can be triggered by digital screen time, seasonal allergies, contact lens wear, and AC use. In fact, 75% to 90% of all dry eye patients have dry eye flares, with an average of more than five episodes per year. In this episode, Dr. Whitley chats with Dr. Adam Ramsey of Socialite Vision in Palm Beach Gardens, Florida, about his early experience with Eysuvis in his practice.
Click Here to read the transcript of this podcast.